Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC

Stock Information for Viomi Technology Co. Ltd

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Viomi Technology Co. Ltd

Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development
GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era
Sidoti Events, LLC's Year-End Virtual Investor Conference
Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025
Cardiff Oncology to Present at Sidoti's Year-End Virtual Investor Conference
Cardiff Oncology to Present at the Piper Sandler 37th Annual Healthcare Conference
Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update
Cardiff Oncology to Participate in Two Upcoming Investor Conferences

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.